PT  - JOURNAL ARTICLE
AU  - Nunley, Pierce
AU  - Frank, Kelly
AU  - Stone, Marcus
TI  - Patient Selection in Cervical Disc Arthroplasty
AID  - 10.14444/7088
DP  - 2020 Aug 01
TA  - International Journal of Spine Surgery
PG  - S29--S35
VI  - 14
IP  - s2
4099  - https://www.ijssurgery.com/content/14/s2/S29.short
4100  - https://www.ijssurgery.com/content/14/s2/S29.full
SO  - Int J Spine Surg2020 Aug 01; 14
AB  - Background: Patient selection for cervical disc arthroplasty (CDA) in the United States remains a topic of debate among surgeons. Many surgeons base US patient selection for CDA implantation on the Food and Drug Administration (FDA) indications/contraindications. While off-label use does occur, the frequency and extent of off-label use in the US remains largely unknown. Outside the United States, patient selection is notably less stringent; however such data also remain largely unpublished or presented/published with a low level of evidence. Here, we will review the current approved US on-label patient selection criteria for CDA and discuss the rationale and supporting evidence to expand these criteria in the United States.Methods: A PubMed literature search was completed using the keywords “cervical disc arthroplasty” and “cervical disc replacement.” The articles were evaluated by the authors for patient selection criteria.Conclusions: The current published data do not conclusively prove that the patients excluded from CDA by strict adherence to FDA indications would benefit from CDA surgery over anterior cervical discectomy and fusion. As surgeons, it is a difficult decision regarding when to expand indications to include off-label use of CDA. In our practice, generally CDA patient selection agrees with the FDA indications and contraindications, as there is a lack of level 1 evidence to confirm effectiveness of CDA outside of the current FDA indications. We will likely need more well-constructed studies to include prospective and controlled trials that specifically evaluate the “off-label” applications before US surgeons are convinced to expand indications and insurance companies agree to reimburse.